AiroAV Antivirus Report: INOVIO’s COVID-19 DNA Vaccine INO-4800 Demonstrates Strong Neutralizing Antibody and T Cell Immune Responses in Preclinical Fashions

INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models

PLYMOUTH MEETING, Pa., Might 20, 2020 /PRNewswire/ — INOVIO (NASDAQ:INO) at the moment introduced the publication of the preclinical examine knowledge for IN0-4800, its COVID-19 DNA vaccine, demonstrating strong neutralizing antibody and T cell immune responses towards coronavirus SARS-CoV-2. The examine was printed within the peer-reviewed journal Nature Communications titled, “Immunogenicity of a DNA vaccine candidate for COVID-19” by INOVIO scientists and collaborators from The Wistar Institute, the College of Texas, Public Well being England, Fudan College, and Advaccine.

Dr. Kate Broderick, INOVIO’s Senior Vice President of R&D and the Workforce Lead for COVID-19 vaccine growth, mentioned, “These optimistic preclinical outcomes from our COVID-19 DNA vaccine (INO-4800) not solely spotlight the efficiency of our DNA medicines platform, but in addition construct on our beforehand reported optimistic Part 1/2a knowledge from our vaccine towards the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralization from a equally designed vaccine INO-4700. The potent neutralizing antibody and T cell immune responses generated in a number of animal fashions are supportive of our at present on-going INO-4800 medical trials.”

INO-4800 targets the foremost floor antigen Spike protein of SARS-CoV-2 virus, which causes COVID-19 illness. The research demonstrated that vaccination with INO-4800 generated strong binding and neutralizing antibody in addition to T cell responses in mice and guinea pigs. Importantly, the authors demonstrated virus neutralizing exercise utilizing three separate neutralization assays testing the vaccine’s skill to generate antibodies which might block virus an infection by: 1) an assay utilizing reside SARS-CoV-2 viruses; 2) an assay utilizing a pseudo-virus assay, the place one other virus shows the SARS-CoV-2 Spike protein; and, three) a novel high-throughput surrogate neutralization assay measuring the power of INO-4800-induced antibodies to dam SARS-CoV-2 Spike binding to the host ACE2 receptor. Examine authors additionally detected these antibodies within the lungs of the vaccinated animals which could possibly be essential in offering safety from SARS-CoV-2. As well as, excessive ranges of Spike-specific T cell responses had been noticed with INO-4800 vaccination, which could possibly be essential in mediating safety from the virus an infection. Collectively, this preclinical dataset demonstrates that INO-4800 is a promising COVID-19 vaccine candidate towards this rising illness risk.

Dr. J. Joseph Kim, INOVIO’s President & CEO, mentioned, “INOVIO and our collaborators are working diligently to advance INO-4800 to assist battle the present pandemic. We’re planning to make the most of these optimistic preclinical outcomes together with our upcoming animal problem knowledge and security and immune responses knowledge from our Part 1 research to assist quickly advancing this summer season to a big, randomized Part 2/three medical trial.”

INOVIO’s swift progress in COVID-19 vaccine growth relies on the best suitability of its DNA drugs platform to quickly develop vaccines towards rising viruses with pandemic potential. INOVIO was the primary to advance its DNA vaccine INO-4700 towards MERS-CoV, a associated coronavirus, into analysis in people in a collaboration with GeneOne Life Science and the Walter Reed Military Institute of Analysis. INO-4700 is the one MERS-CoV vaccine with optimistic knowledge from a Part 1/2a medical trial, and INOVIO is at present making ready to provoke a bigger Part 2 vaccine trial for INO-4700 within the Center East the place most MERS viral outbreaks have occurred. These efforts are supported by CEPI funding.

About INO-4800

INO-4800 is INOVIO’s DNA vaccine candidate created to guard towards the novel coronavirus SARS-CoV-2, which causes COVID-19. INO-4800 was designed utilizing INOVIO’s proprietary DNA drugs platform quickly after the publication of the genetic sequence of the coronavirus that causes COVID-19. INOVIO has deep expertise working with coronaviruses and is the one firm with a Part 2a vaccine for a associated coronavirus that causes Center East Respiratory Syndrome (MERS).

About INOVIO’s World Coalition Advancing INO-4800

INOVIO has assembled a worldwide coalition of collaborators, companions and funders to quickly advance INO-4800. R&D collaborators so far embody the Wistar Institute, the College of Pennsylvania, the College of Texas, Fudan College and the Laval College. INOVIO has partnered with Advaccine and the Worldwide Vaccine Institute to advance medical trials of INO-4800 in China and South Korea, respectively. INOVIO can be assessing preclinical efficacy of INO-4800 in a number of animal problem fashions with Public Well being England (PHE) and Commonwealth Scientific and Industrial Analysis Group (CSIRO) in Australia. INOVIO can be working with a workforce of contract producers together with VGXI, Inc., Richter-Helm BioLogics, and Ology Biosciences to supply INO-4800 and searching for extra exterior funding and partnerships to scale up the manufacturing capacities to fulfill the pressing world demand for a protected and efficient vaccine. To this point, the Coalition for Epidemic Preparedness Improvements (CEPI), the Invoice & Melinda Gates Basis, and the US Division of Protection have contributed vital funding to the development and manufacturing of INO-4800.

About INOVIO’s DNA Medicines Platform

INOVIO has 15 DNA drugs medical applications at present in growth centered on HPV-associated ailments, most cancers, and infectious ailments, together with coronaviruses related to MERS and COVID-19 ailments being developed below grants from the Coalition for Epidemic Preparedness Improvements (CEPI). DNA medicines are composed of optimized DNA plasmids, that are small circles of double-stranded DNA which can be synthesized or reorganized by a pc sequencing expertise and designed to supply a particular immune response within the physique.

INOVIO’s DNA medicines ship optimized plasmids immediately into cells intradermally or intramuscularly utilizing INOVIO’s proprietary hand-held sensible gadget referred to as CELLECTRA®. The CELLECTRA gadget makes use of a short electrical pulse to reversibly open small pores within the cell to permit the plasmids to enter, overcoming a key limitation of different DNA and different nucleic acid approaches, equivalent to mRNA. As soon as contained in the cell, the DNA plasmids allow the cell to supply the focused antigen. The antigen is processed naturally within the cell and triggers the specified T cell and antibody-mediated immune responses. Administration with the CELLECTRA gadget ensures that the DNA drugs is effectively delivered immediately into the physique’s cells, the place it might go to work to drive an immune response. INOVIO’s DNA medicines don’t intrude with or change in any means a person’s personal DNA. The benefits of INOVIO’s DNA drugs platform are how briskly DNA medicines may be designed and manufactured, the soundness of the merchandise which don’t require freezing in storage and transport, and the strong immune response, security profile, and tolerability which have been demonstrated in medical trials.

With greater than 2,000 sufferers receiving INOVIO investigational DNA medicines in additional than 6,000 purposes throughout a variety of medical trials, INOVIO has a powerful monitor document of quickly producing DNA drugs candidates with potential to fulfill pressing world well being wants.


INOVIO is a biotechnology firm centered on quickly bringing to market exactly designed DNA medicines to guard and deal with individuals from infectious ailments, most cancers, and ailments related to HPV. INOVIO is the primary and solely firm to have clinically demonstrated DNA drugs may be delivered immediately into cells within the physique through a proprietary sensible gadget to supply a sturdy and tolerable immune response. Particularly, INOVIO’s lead candidate VGX-3100, at present in Part three trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Part 2b medical trial. Excessive-risk HPV is accountable for 70% of cervical most cancers, 91% of anal most cancers, and 69% of vulvar most cancers. Additionally in growth are applications concentrating on HPV-related cancers and a uncommon HPV-related illness, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate most cancers; in addition to externally funded infectious illness DNA vaccine growth applications in Zika, Lassa fever, Ebola, HIV, and coronaviruses related to MERS and COVID-19 ailments. Companions and collaborators embody Advaccine, ApolloBio Company, AstraZeneca, The Invoice & Melinda Gates Basis, Coalition for Epidemic Preparedness Improvements (CEPI), Protection Superior Analysis Tasks Company (DARPA)/Division of Protection (DOD), GeneOne Life Science/VGXI, HIV Vaccines Trial Community, Worldwide Vaccine Institute (IVI), Medical CBRN Protection Consortium (MCDC), Nationwide Most cancers Institute, Nationwide Institutes of Well being, Nationwide Institute of Allergy and Infectious Ailments, Ology Bioservices, the Parker Institute for Most cancers Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Roche/Genentech, College of Pennsylvania, Walter Reed Military Institute of Analysis, and The Wistar Institute. INOVIO is also a proud recipient of 2020 Girls on Boards “W” designation recognizing firms with greater than 20% ladies on their board of administrators. For extra info, go to

Airo Safety AiroAV

Author: Airoav

Leave a Reply

Your email address will not be published. Required fields are marked *